TranScend Therapeutics-B (06628) proposes the appointment of Xu Hanshen as a non-executive director.

Transcenta Holding Limited (Stock Code: 06628) announced that Dr. Hanshen Xu will be appointed as a Non-Executive Director; and (ii) Dr. Jun Bao will be appointed as an Independent Non-Executive Director, subject in each case to approval by the shareholders of the Company at the annual general meeting to be held on June 30, 2026.

Zhitong FinanceJun 4 07:21 ET

Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7%

MT NewswiresMay 26 23:50 ET

Transcenta Holding Limited (06628.HK) announced receipt of a HiCB out-licensing milestone payment and steady growth in its CDMO business.

Transcenta Holding Limited (06628.HK) announced that the company has received a milestone payment of RMB 7 million from the out-licensing of its HiCB (Highly Intensified Continuous Bioprocessing) platform, and its CDMO business has also achieved significant progress.

Zhitong FinanceMay 26 04:35 ET

Express News | Transcenta Holding Ltd - Negotiating Contracts for Ind Development and Sirna Gmp DP Production

ReutersMay 26 04:33 ET

Transcenta Postpones AGM and Adjusts Share Register Closure Dates

TipRanksMay 14 07:49 ET

TRANSCENTA-B: 2025 ANNUAL REPORT

HKEXApr 28 04:45 ET · Announcements